Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC	Locally Advanced Rectal Adenocarcinoma; Neoadjuvant Chemoradiation; Neoadjuvant Immunotherapy	Not yet recruiting	Phase 2 / Phase 3	2026-06-17		NCT07596290

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing Friendship Hospital	120
Peking Union Medical College	33
Peking University Cancer Hospital & Institute	189

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.

Clinical trials